These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 11685032)
1. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Sperti C; Pasquali C; Chierichetti F; Liessi G; Ferlin G; Pedrazzoli S Ann Surg; 2001 Nov; 234(5):675-80. PubMed ID: 11685032 [TBL] [Abstract][Full Text] [Related]
3. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094 [TBL] [Abstract][Full Text] [Related]
4. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study. Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314 [TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
6. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics. Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193 [TBL] [Abstract][Full Text] [Related]
7. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067 [TBL] [Abstract][Full Text] [Related]
8. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771 [TBL] [Abstract][Full Text] [Related]
9. Systematic review of the utility of 18-FDG PET in the preoperative evaluation of IPMNs and cystic lesions of the pancreas. Srinivasan N; Koh YX; Goh BKP Surgery; 2019 May; 165(5):929-937. PubMed ID: 30577952 [TBL] [Abstract][Full Text] [Related]
10. The value of Regenet N; Sauvanet A; Muscari F; Meunier B; Mariette C; Adham M; Moutardier V; Delpero JR; Regimbeau JM; Pessaux P; Paye F; Sa Cunha A; Ansquer C J Visc Surg; 2020 Oct; 157(5):387-394. PubMed ID: 32005594 [TBL] [Abstract][Full Text] [Related]
11. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions]. Voth M; Opfermann T; Gottschild D Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634 [TBL] [Abstract][Full Text] [Related]
12. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis of pancreatic carcinoma: role of FDG PET. Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289 [TBL] [Abstract][Full Text] [Related]
14. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879 [TBL] [Abstract][Full Text] [Related]
15. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532 [TBL] [Abstract][Full Text] [Related]
17. The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions. Papós M; Takács T; Trón L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Pávics L Clin Nucl Med; 2002 Mar; 27(3):197-201. PubMed ID: 11852308 [TBL] [Abstract][Full Text] [Related]
18. The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. Mansour JC; Schwartz L; Pandit-Taskar N; D'Angelica M; Fong Y; Larson SM; Brennan MF; Allen PJ J Gastrointest Surg; 2006 Dec; 10(10):1354-60. PubMed ID: 17175454 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191 [TBL] [Abstract][Full Text] [Related]
20. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]